Back
Verrica Pharmaceuticals Quote, Financials, Valuation and Earnings
Sponsored
VRCA
Sponsored
Yours Free! Top SIX AI Dividend Stocks Right Now
NO CREDIT CARD REQUIRED!
Sell
25
VRCA
Verrica Pharmaceuticals
Last Price:
0.92
Seasonality Move:
34.27%
7 Day Trial
ALL ACCESS PASS
$
7
"This Changes Everything" - Trump Hands Millions Massive IRS Gift
Learn More HereVerrica Pharmaceuticals Price Quote
$0.92
-0.04 (-4.37%)
(Updated: November 12, 2024 at 5:55 PM ET)
Verrica Pharmaceuticals Key Stats
Sell
25
Verrica Pharmaceuticals (VRCA)
is a Sell
Day range:
$0.83 - $0.98
52-week range:
$0.70 - $11.41
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4.86
P/B ratio:
0%
Volume:
1.2M
Avg. volume:
1.1M
1-year change:
-68.72%
Market cap:
$43.9M
Revenue:
$5.1M
EPS:
$-1.84
How Much Does Verrica Pharmaceuticals Make?
-
How Much Are Verrica Pharmaceuticals's Sales Annually?
VRCA Revenues are $5.1M -
How Much Profit Does Verrica Pharmaceuticals's Make A Year?
VRCA net income is -$67M
Is Verrica Pharmaceuticals Growing As A Company?
Data Unavailable
Verrica Pharmaceuticals Stock Price Performance
-
Did Verrica Pharmaceuticals Stock Go Up Last Month?
Verrica Pharmaceuticals share price went down by -28.21% last month -
Did VRCA's Share Price Rise Over The Last Year?
VRCA share price fell by -68.72% over the past 1 year
What Is Verrica Pharmaceuticals 52-Week High & Low?
-
What Is Verrica Pharmaceuticals’s 52-Week High Share Price?
Verrica Pharmaceuticals has traded as high as $11.41 over the past 52 weeks -
What Is Verrica Pharmaceuticals’s 52-Week Low Share Price?
Verrica Pharmaceuticals has traded as low as $0.70 over the past 52 weeks
Verrica Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Verrica Pharmaceuticals?
-
How Much Debt Does Verrica Pharmaceuticals Have?
Total long term debt quarterly is $43.3M -
How Much Cash Does Verrica Pharmaceuticals Have?
Cash and short term investments quarterly total is $23M -
What Is Verrica Pharmaceuticals’s Book Value Per Share?
Book value per share is -0.75
Is Verrica Pharmaceuticals Cash Flow Positive?
-
What Is VRCA Cash Flow From Operations?
Cash flow from operations (TTM) is -$59.4M -
What Is Verrica Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$1.7M -
What Is Verrica Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$254K
Verrica Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
VRCA return on invested capital is -184.44% -
What Is Verrica Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -128.78% -
What Is VRCA Return On Equity?
ROE is a measure of profitability and is -2619.46%
Verrica Pharmaceuticals Earnings Date & Stock Price
-
What Is Verrica Pharmaceuticals's Stock Price Today?
A single share of VRCA can be purchased today for 0.96 -
What Is Verrica Pharmaceuticals’s Stock Symbol?
Verrica Pharmaceuticals trades on the nasdaq under the ticker symbol: VRCA -
When Is Verrica Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Verrica Pharmaceuticals is scheduled on February 28, 2025 -
When Is VRCA's next ex-dividend date?
Verrica Pharmaceuticals's next ex-dividend date is May 7, 2020 -
How To Buy Verrica Pharmaceuticals Stock?
You can buy Verrica Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Verrica Pharmaceuticals Competitors
-
Who Are Verrica Pharmaceuticals's Competitors?
Below is a list of companies who compete with Verrica Pharmaceuticals or are related in some way:
Verrica Pharmaceuticals Dividend Yield
-
What Is VRCA Dividend Yield?
Verrica Pharmaceuticals’s dividend yield currently is 0% -
What Is Verrica Pharmaceuticals’s Payout Ratio?
Verrica Pharmaceuticals’s payout ratio is 0% -
When Did Verrica Pharmaceuticals Last Pay A Dividend?
The latest dividend pay date is November 13, 2024 -
What Is Verrica Pharmaceuticals’s Dividend Per Share?
Verrica Pharmaceuticals pays a dividend of $0.00 per share
Verrica Pharmaceuticals Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -26.45% |
Revenue: | 0% | -133.85% |
Analyst Recommendations
Buy Recommendations: | 2 |
---|---|
Hold Recommendations: | 4 |
Sell Recommendations: | 0 |
Price Target: | 6.33 |
Upside from Last Price: | 558.35% |